New Therapeutic Agents in Thrombosis and Thrombolysis

the long version

Presents new chapters discussing the latest research on low-molecular-weight heparins, as well as agents such as pentasaccharide, TFP1, soluble thrombomodulin, and alfimeprase.Completely revised and expanded throughout, New Therapeutic Agents in Thrombosis and Thrombolysis details strategies totarget conventional and recently characterized pathways of hemostasisminimize the prothrombotic function of activated plateletsassess the biochemical and pharmacological effects of antithrombotic agentsand discussesthe use of animal models for determination of antithrombotic drug efficacyantithrombotic therapy as a key component of cardiovascular disease managementthe management of thromboembolic events in children and pregnant womenSupplemented with more than 2000 contemporary references, New Therapeutic Agents in Thrombosis and Thrombolysis is an authoritative source for cardiologists, internists, primary care physicians, vascular medicine specialists, cardiovascular and vascular surgeons, hematologists, pulmonologists, critical care physicians, pharmacologists, pharmaceutical researchers, and fellows, residents, and graduate and medical school students in these disciplines.